Form 4: BioLife Solutions EVP Aby J. Mathew Sells Shares Under 10b5-1 Trading Plan
SEC Form 4
Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc., sold a total of 20,800 shares of common stock on December 16 and 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Aby J. Mathew, the EVP & Chief Scientific Officer of BioLife Solutions Inc. (BLFS), reported the sale of company stock.
- The transactions occurred on December 16 and 17, 2024.
- A total of 7,604 shares were sold on December 16 at a weighted average price of $27.33, with individual prices ranging from $26.88 to $28.33.
- On December 17, 13,196 shares were sold at a weighted average price of $27.16, with individual prices ranging from $26.62 to $27.48.
- The sales were executed under a Rule 10b5-1(c) trading plan adopted on June 14, 2024.
- Following these transactions, Mathew directly owns 263,119 shares of BioLife Solutions Inc.
Sentiment
Score: 5
Explanation: The document is neutral as it simply reports stock sales by an executive under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Risks
- Executive stock sales can sometimes be perceived negatively by investors, although these sales were conducted under a pre-arranged trading plan.
Industry Context
Insider sales are a common occurrence in publicly traded companies and are often part of executives' compensation packages or personal financial planning. The use of Rule 10b5-1 plans allows insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information.
Comparison to Industry Standards
- Executive stock sales are a normal part of corporate activity.
- Companies like Thermo Fisher Scientific, Danaher, and Agilent Technologies also see regular insider trading activity.
- The key is whether the sales are conducted under pre-arranged plans like Rule 10b5-1, which is considered a best practice.
Stakeholder Impact
- Shareholders may react to insider sales, although the existence of a 10b5-1 plan mitigates concerns.
- The impact on employees, customers, suppliers, and creditors is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 06/14/2024 | Date of adoption of the Rule 10b5-1(c) trading plan |
| 12/16/2024 | Date of first stock sale: 7,604 shares at ~$27.33 |
| 12/17/2024 | Date of second stock sale: 13,196 shares at ~$27.16 |
| 12/19/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.